PopVax is a full-stack biotech founded in late 2021 that develops novel mRNA vaccines and therapeutics with a focus on thermostable formulations suitable for distribution in low-resource settings. Its platform combines a proprietary mRNA architecture for virus-like particle immunogen display, PopVax-designed ionizable lipids for lipid nanoparticle delivery, and machine-learning-driven protein design. The company operates the RNA Foundry, an integrated R&D and process-development facility in Hyderabad, and employs 70 staff across computational, experimental, analytical, and quality functions. PopVax’s lead program is a broadly protective next-generation COVID-19 vaccine expected to enter U.S. clinical trials in early 2025; six additional vaccine candidates are in pre-clinical development with plans for five clinical trials over the next two years. Financially, PopVax has secured a US$1.15 million project grant from the Bill & Melinda Gates Foundation, building on an earlier US$100 thousand grant awarded in 2021. These non-dilutive funds support the development and animal testing of lipid-polymer delivery formulations designed to keep mRNA vaccines stable at standard refrigeration temperatures.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2024